Zhitong Finance App News, Hisilco (002653.SZ) announced that the company's subsidiary Shanghai Hisense Pharmaceutical Technology Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. HSK45019 tablets, HSK50042 tablets, injectable HSK55718, and HSK36357 capsules were approved for clinical trials. The corresponding indications are: inflammatory bowel disease, respiratory disease, acute pain, and muscular dystrophy.

Zhitong Finance App News, Hisilco (002653.SZ) announced that the company's subsidiary Shanghai Hisense Pharmaceutical Technology Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. HSK45019 tablets, HSK50042 tablets, injectable HSK55718, and HSK36357 capsules were approved for clinical trials. The corresponding indications are: inflammatory bowel disease, respiratory disease, acute pain, and muscular dystrophy.